Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Monday

Atossa Therapeutics (NASDAQ:ATOS) is anticipated to issue its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect Atossa Therapeutics to post earnings of ($0.06) per share for the quarter.

Atossa Therapeutics (NASDAQ:ATOS) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, analysts expect Atossa Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atossa Therapeutics Price Performance

Shares of ATOS opened at $0.60 on Friday. The stock has a market cap of $77.64 million, a price-to-earnings ratio of -2.73 and a beta of 1.20. The firm has a 50 day simple moving average of $0.76 and a 200-day simple moving average of $1.07. Atossa Therapeutics has a 1-year low of $0.60 and a 1-year high of $1.97.

Analyst Upgrades and Downgrades

ATOS has been the subject of several research analyst reports. Ascendiant Capital Markets boosted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Atossa Therapeutics in a report on Wednesday, March 26th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Atossa Therapeutics stock. Bank of America Corp DE grew its stake in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 111,475 shares of the company’s stock after buying an additional 37,809 shares during the quarter. Bank of America Corp DE owned about 0.09% of Atossa Therapeutics worth $105,000 as of its most recent filing with the Securities and Exchange Commission. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.